Industry finds flaws Indian per-capita income-linked price approach for patented drugs
This article was originally published in Scrip
An Indian government panel's suggestion to set prices of patented medicines using a per capita income-linked reference pricing model has sparked criticism from several quarters of the pharmaceutical industry, which believes that the approach is flawed and that a suitable access model should be considered instead.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.